3 Formulation Maker, Glycol Producer and Pizza Chain Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, India Glycols and Jubilant FoodWorks
- October 15, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Lincoln Pharma Rs 542.90, P/E 11.64. India Glycols Rs 349.85, P/E 7.58. Jubilant FoodWorks Rs 425.70, P/E 62.77. Closing prices of 14 Oct 2026.
Quick Answer
Formulation maker, glycol producer and pizza chain stocks with the clearest long-term roadmaps today include Lincoln Pharma in formulations sold in India and emerging export markets, India Glycols in glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and Jubilant FoodWorks in Domino’s Pizza stores across India and neighbouring markets, along with newer food brands. FY26 revenue growth was 9.1% at Lincoln Pharma, 11.5% at India Glycols and 17.2% at Jubilant FoodWorks. P/E stands at 11.64 for Lincoln Pharma (industry 37.59), 7.58 for India Glycols (industry 54.53) and 62.77 for Jubilant FoodWorks (industry 61.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Formulation maker, glycol producer and pizza chain stocks give investors exposure to medicines, chemicals and food outlets used every day. Volumes, store additions and margins decide how much of that demand turns into profit.
This list covers three formulation maker, glycol producer and pizza chain stocks: Lincoln Pharmaceuticals for formulations sold in India and emerging export markets, India Glycols for glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock and Jubilant FoodWorks for Domino’s Pizza stores across India and neighbouring markets, along with newer food brands. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Formulation Maker, Glycol Producer and Pizza Chain Stocks?
Formulation maker, glycol producer and pizza chain stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Formulation Maker, Glycol Producer and Pizza Chain Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three formulation maker, glycol producer and pizza chain stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 542.90 | 1,123 | 11.64 | 37.59 | 11.60% | 0.01 |
| India Glycols | 349.85 | 2,397 | 7.58 | 54.53 | 9.98% | 0.58 |
| Jubilant FoodWorks | 425.70 | 28,248 | 62.77 | 61.79 | 18.69% | 2.14 |
Among healthcare, chemicals and consumer stocks, valuations sit close to their industry P/E multiples.
Why Do Formulation Maker, Glycol Producer and Pizza Chain Stocks Have a Strong Roadmap in India?
Formulation maker, glycol producer and pizza chain stocks have a strong roadmap in India because export demand for medicines, ethanol blending and eating out keep adding volumes for these firms. Three drivers stand out.
- Pharma exports: Emerging markets add demand for formulations.
- Renewable chemicals: Ethanol and bio-based chemicals gain policy support.
- Eating out: Quick-service outlets reach more towns.
Lincoln Pharmaceuticals: Formulations for India and Export Markets Build the Next Leg
Lincoln Pharma’s roadmap rests on formulations sold in India and emerging export markets, with a broad product list supporting revenue.
Revenue grew from Rs 482.12 crore in FY22 to Rs 704.48 crore in FY26, a 46.1% rise, and FY26 revenue was 9.1% higher than FY25. FY26 net profit rose 6.7% to Rs 87.89 crore. Over four years, net profit rose from Rs 69.36 crore in FY22 to Rs 87.89 crore. In Q1 FY27, revenue grew 19.0% to Rs 201.54 crore, and net profit rose 30.9% to Rs 36.23 crore.
Debt to equity is 0.01 and return on equity is 11.60%. The dividend yield is 0.32%. At a P/E of 11.64 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: The P/E of 11.64 against an industry P/E of 37.59 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
India Glycols: Green Chemicals and Ethanol Build the Next Leg
India Glycols’ roadmap rests on glycols, spirits and ethanol, and specialty chemicals made from renewable feedstock, with ethanol blending and chemical demand supporting volumes.
Revenue grew from Rs 2,889.84 crore in FY22 to Rs 4,216.34 crore in FY26, a 45.9% rise, and FY26 revenue was 11.5% higher than FY25. FY26 net profit rose 26.8% to Rs 292.76 crore. In Q1 FY27, revenue grew 19.3% to Rs 2,988.82 crore, and net profit rose 32.2% to Rs 96.83 crore. Operating margin was 7.12% in FY26.
Debt to equity is 0.58 and return on equity is 9.98%. FY26 operating cash flow was Rs 769.16 crore against capital expenditure of Rs 823.48 crore. India Glycols paid a dividend of Rs 7.5 per share for FY26, a yield of 2.10%. At a P/E of 7.58 against an industry P/E of 54.53, the stock trades below its industry multiple.
What to watch: The P/E of 7.58 against an industry P/E of 54.53 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Jubilant FoodWorks: Domino’s Store Network Anchors the Roadmap
Jubilant FoodWorks’ roadmap rests on Domino’s Pizza stores across India and neighbouring markets, along with newer food brands, with store additions and delivery reach supporting sales.
Revenue grew from Rs 4,437.48 crore in FY22 to Rs 9,586.64 crore in FY26, a 116.0% rise, and FY26 revenue was 17.2% higher than FY25. FY26 net profit rose 54.4% to Rs 386.03 crore. In Q1 FY27, revenue grew 13.6% to Rs 2,588.34 crore, and net profit rose 6.0% to Rs 100.03 crore. Operating margin was 20.96% in FY26 and 20.37% in Q1 FY27 against 20.21% a year earlier.
Debt to equity is 2.14 and return on equity is 18.69%. FY26 operating cash flow was Rs 1,893.55 crore against capital expenditure of Rs 1,009.93 crore. Jubilant FoodWorks paid a dividend of Rs 1.2 per share for FY26, a yield of 0.28%. At a P/E of 62.77 against an industry P/E of 61.79, the stock trades in line with its industry multiple.
What to watch: Debt to equity of 2.14 is on the higher side, and net profit margin is only 4.0%, so small cost changes move earnings.
Best Formulation Maker, Glycol Producer and Pizza Chain Stocks in India: Lincoln Pharma vs India Glycols vs Jubilant FoodWorks on Key Financials
Among the best formulation maker, glycol producer and pizza chain stocks in India, Lincoln Pharma leads on the lowest debt to equity; India Glycols leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Jubilant FoodWorks leads on FY26 revenue growth and FY26 net profit growth. The table puts the numbers side by side.
| Metric | Lincoln Pharma | India Glycols | Jubilant FoodWorks |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 704.48 | 4,216.34 | 9,586.64 |
| FY26 revenue growth | 9.1% | 11.5% | 17.2% |
| FY26 net profit (Rs Cr) | 87.89 | 292.76 | 386.03 |
| FY26 net profit growth | 6.7% | 26.8% | 54.4% |
| Q1 FY27 revenue growth (YoY) | 19.0% | 19.3% | 13.6% |
| Q1 FY27 net profit growth (YoY) | 30.9% | 32.2% | 6.0% |
| Return on equity | 11.60% | 9.98% | 18.69% |
| P/E ratio | 11.64 | 7.58 | 62.77 |
| Debt to equity | 0.01 | 0.58 | 2.14 |
| Dividend yield | 0.32% | 2.10% | 0.28% |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Formulation Maker, Glycol Producer and Pizza Chain Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen formulation maker, glycol producer and pizza chain stocks and shortlist formulation maker, glycol producer and pizza chain stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Formulation Maker, Glycol Producer and Pizza Chain Stocks
- Debt and cash flow: Jubilant FoodWorks has debt to equity of 2.14.
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Lincoln Pharma, India Glycols and Jubilant FoodWorks live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover formulations, glycols and quick-service restaurants. Lincoln Pharma leads on the lowest debt to equity; India Glycols leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; Jubilant FoodWorks leads on FY26 revenue growth and FY26 net profit growth.
Across formulation maker, glycol producer and pizza chain stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the formulation maker, glycol producer and pizza chain stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Formulation Maker, Glycol Producer and Pizza Chain Stocks
Which are the best formulation maker, glycol producer and pizza chain stocks in India with a strong roadmap?
Ans. Lincoln Pharmaceuticals, India Glycols and Jubilant FoodWorks stand out for their roadmaps in formulations, glycols and quick-service restaurants. FY26 revenue growth was 9.1% at Lincoln Pharma, 11.5% at India Glycols and 17.2% at Jubilant FoodWorks, and return on equity ranges from 9.98% to 18.69%.
Is Lincoln Pharmaceuticals a good stock to buy now?
Ans. Lincoln Pharmaceuticals has a debt to equity ratio of 0.01, a return on equity of 11.60% and a P/E of 11.64 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Lincoln Pharma, India Glycols and Jubilant FoodWorks?
Ans. The P/E ratio is 11.64 for Lincoln Pharma (industry 37.59), 7.58 for India Glycols (industry 54.53) and 62.77 for Jubilant FoodWorks (industry 61.79). Only Jubilant FoodWorks trades at or above the industry multiple.
Which of these formulation maker, glycol producer and pizza chain stocks has the highest return on equity?
Ans. Jubilant FoodWorks has the highest return on equity at 18.69%, followed by Lincoln Pharmaceuticals at 11.60% and India Glycols at 9.98%.
What are the risks of investing in formulation maker, glycol producer and pizza chain stocks?
Ans. The main risks are debt and cash flow, consumer demand, input costs and quarterly trends. Jubilant FoodWorks has debt to equity of 2.14.
How did Lincoln Pharma, India Glycols and Jubilant FoodWorks perform in Q1 FY27?
Ans. Lincoln Pharmaceuticals reported revenue of Rs 201.54 crore, up 19.0% year on year, and net profit rose 30.9% to Rs 36.23 crore. India Glycols reported revenue of Rs 2,988.82 crore, up 19.3% year on year, and net profit rose 32.2% to Rs 96.83 crore. Jubilant FoodWorks reported revenue of Rs 2,588.34 crore, up 13.6% year on year, and net profit rose 6.0% to Rs 100.03 crore.
Do formulation maker, glycol producer and pizza chain stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.32% for Lincoln Pharma, 2.10% for India Glycols and 0.28% for Jubilant FoodWorks, based on dividends declared for FY26.
How can I invest in formulation maker, glycol producer and pizza chain stocks in India?
Ans. You can buy formulation maker, glycol producer and pizza chain stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
